# Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

> **NCT05138705** · PHASE4 · COMPLETED · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 380 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Quadrivalent Influenza Virus Split Vaccine

## Key facts

- **NCT ID:** NCT05138705
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-08-05
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05138705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05138705, "Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05138705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*